 Rachel Rabinovitch
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 62 | 2025 | 2253 | 4.120 |
Why?
| | Mastectomy, Segmental | 29 | 2025 | 93 | 2.190 |
Why?
| | Hodgkin Disease | 8 | 2022 | 138 | 1.540 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 8 | 2023 | 123 | 1.500 |
Why?
| | Brachytherapy | 10 | 2019 | 121 | 1.350 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 8 | 2025 | 56 | 1.340 |
Why?
| | Neoplasm Staging | 34 | 2020 | 1389 | 1.110 |
Why?
| | Mastectomy | 8 | 2025 | 137 | 1.110 |
Why?
| | Neoplasm Recurrence, Local | 14 | 2025 | 1079 | 1.100 |
Why?
| | Mediastinal Neoplasms | 3 | 2017 | 45 | 1.080 |
Why?
| | Radiotherapy, Adjuvant | 18 | 2025 | 220 | 1.050 |
Why?
| | Radiotherapy, Conformal | 7 | 2016 | 70 | 0.950 |
Why?
| | Radiation Pneumonitis | 1 | 2024 | 29 | 0.880 |
Why?
| | Combined Modality Therapy | 25 | 2024 | 1236 | 0.870 |
Why?
| | Lymphoma, Follicular | 4 | 2023 | 40 | 0.800 |
Why?
| | Radiation Oncologists | 1 | 2021 | 5 | 0.740 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 1692 | 0.700 |
Why?
| | Carcinoma, Ductal, Breast | 10 | 2016 | 83 | 0.600 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 6 | 2020 | 130 | 0.560 |
Why?
| | Female | 80 | 2025 | 73304 | 0.530 |
Why?
| | Breast | 3 | 2013 | 151 | 0.510 |
Why?
| | Middle Aged | 53 | 2025 | 33479 | 0.500 |
Why?
| | Mammography | 5 | 2019 | 154 | 0.500 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2024 | 99 | 0.490 |
Why?
| | Humans | 108 | 2025 | 137585 | 0.490 |
Why?
| | SEER Program | 7 | 2019 | 227 | 0.490 |
Why?
| | Aged, 80 and over | 20 | 2025 | 7635 | 0.480 |
Why?
| | Prognosis | 16 | 2024 | 4030 | 0.460 |
Why?
| | Lymphoma, B-Cell | 1 | 2016 | 106 | 0.460 |
Why?
| | Radiotherapy Dosage | 13 | 2025 | 268 | 0.440 |
Why?
| | Aged | 40 | 2025 | 23961 | 0.440 |
Why?
| | Transplantation Conditioning | 5 | 2024 | 170 | 0.440 |
Why?
| | Lymph Nodes | 5 | 2016 | 491 | 0.430 |
Why?
| | Kaplan-Meier Estimate | 6 | 2020 | 889 | 0.430 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 29 | 0.420 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1266 | 0.420 |
Why?
| | Treatment Outcome | 21 | 2025 | 10811 | 0.410 |
Why?
| | Neoplasms, Second Primary | 3 | 2020 | 118 | 0.410 |
Why?
| | BRCA2 Protein | 3 | 2020 | 63 | 0.400 |
Why?
| | Radiosurgery | 2 | 2019 | 344 | 0.400 |
Why?
| | Receptor, ErbB-2 | 5 | 2024 | 341 | 0.400 |
Why?
| | Adult | 45 | 2025 | 37929 | 0.390 |
Why?
| | Radiotherapy | 6 | 2015 | 201 | 0.380 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2021 | 87 | 0.380 |
Why?
| | Follow-Up Studies | 11 | 2024 | 5131 | 0.380 |
Why?
| | Healthcare Disparities | 1 | 2018 | 654 | 0.370 |
Why?
| | Mammaplasty | 1 | 2013 | 105 | 0.370 |
Why?
| | Prostatic Neoplasms | 4 | 2022 | 1043 | 0.360 |
Why?
| | Survival Analysis | 9 | 2018 | 1325 | 0.360 |
Why?
| | Delivery of Health Care | 1 | 2018 | 951 | 0.360 |
Why?
| | Lymphoma | 2 | 2025 | 208 | 0.330 |
Why?
| | Whole-Body Irradiation | 5 | 2020 | 78 | 0.320 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2024 | 622 | 0.320 |
Why?
| | BRCA1 Protein | 2 | 2020 | 76 | 0.320 |
Why?
| | Disease-Free Survival | 8 | 2025 | 686 | 0.320 |
Why?
| | Anthracyclines | 1 | 2009 | 42 | 0.310 |
Why?
| | Medical Oncology | 3 | 2021 | 289 | 0.310 |
Why?
| | Radiation Oncology | 5 | 2025 | 82 | 0.300 |
Why?
| | Neoplasms, Radiation-Induced | 3 | 2020 | 92 | 0.300 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 115 | 0.300 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2009 | 127 | 0.300 |
Why?
| | Bile Duct Diseases | 1 | 2008 | 14 | 0.280 |
Why?
| | Graft vs Host Disease | 5 | 2024 | 252 | 0.280 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2008 | 39 | 0.280 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2017 | 73 | 0.280 |
Why?
| | Neoplasm Grading | 6 | 2022 | 307 | 0.280 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 78 | 0.270 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2014 | 142 | 0.270 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 77 | 0.270 |
Why?
| | United States | 16 | 2019 | 14841 | 0.260 |
Why?
| | Prostheses and Implants | 1 | 2007 | 143 | 0.250 |
Why?
| | Trastuzumab | 3 | 2024 | 96 | 0.250 |
Why?
| | Nutritional Support | 1 | 2006 | 34 | 0.250 |
Why?
| | Heart Diseases | 1 | 2009 | 346 | 0.240 |
Why?
| | Orbital Neoplasms | 1 | 2025 | 24 | 0.230 |
Why?
| | Young Adult | 9 | 2025 | 13209 | 0.230 |
Why?
| | Receptors, Estrogen | 4 | 2016 | 436 | 0.230 |
Why?
| | Survival Rate | 8 | 2019 | 1972 | 0.230 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 22 | 0.220 |
Why?
| | Male | 28 | 2025 | 67762 | 0.220 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2023 | 21 | 0.210 |
Why?
| | Time Factors | 5 | 2018 | 6828 | 0.200 |
Why?
| | Neoadjuvant Therapy | 3 | 2025 | 404 | 0.190 |
Why?
| | Flutamide | 2 | 2018 | 5 | 0.190 |
Why?
| | Goserelin | 2 | 2018 | 7 | 0.190 |
Why?
| | Adolescent | 11 | 2025 | 21513 | 0.180 |
Why?
| | Analysis of Variance | 2 | 2015 | 1316 | 0.180 |
Why?
| | Patient Care Planning | 2 | 2021 | 157 | 0.180 |
Why?
| | Head and Neck Neoplasms | 2 | 2010 | 606 | 0.180 |
Why?
| | Neoplasm Invasiveness | 4 | 2019 | 510 | 0.180 |
Why?
| | Cause of Death | 2 | 2016 | 434 | 0.170 |
Why?
| | Bone Neoplasms | 2 | 2018 | 247 | 0.170 |
Why?
| | Survivorship | 1 | 2021 | 52 | 0.170 |
Why?
| | Deoxycytidine | 1 | 2022 | 179 | 0.170 |
Why?
| | Androgen Antagonists | 2 | 2022 | 82 | 0.170 |
Why?
| | Tumor Burden | 4 | 2016 | 309 | 0.170 |
Why?
| | Adenocarcinoma | 2 | 2018 | 940 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2006 | 683 | 0.170 |
Why?
| | Azacitidine | 1 | 2021 | 140 | 0.170 |
Why?
| | Retrospective Studies | 12 | 2025 | 15657 | 0.170 |
Why?
| | Immunoconjugates | 1 | 2021 | 114 | 0.160 |
Why?
| | Clinical Trials as Topic | 5 | 2017 | 1050 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 804 | 0.160 |
Why?
| | Surgical Instruments | 1 | 2000 | 51 | 0.160 |
Why?
| | Antineoplastic Agents | 7 | 2017 | 2129 | 0.160 |
Why?
| | Radiation Injuries | 3 | 2016 | 145 | 0.160 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1276 | 0.160 |
Why?
| | Patient Satisfaction | 2 | 2013 | 660 | 0.150 |
Why?
| | Neoplasms | 2 | 2011 | 2671 | 0.150 |
Why?
| | Vidarabine | 3 | 2018 | 33 | 0.150 |
Why?
| | Leuprolide | 1 | 2018 | 20 | 0.150 |
Why?
| | Practice Guidelines as Topic | 5 | 2017 | 1587 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2018 | 82 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Aquaporin 4 | 1 | 2019 | 94 | 0.150 |
Why?
| | Necrosis | 1 | 2019 | 246 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2022 | 1477 | 0.140 |
Why?
| | Diphosphonates | 1 | 2018 | 66 | 0.140 |
Why?
| | Rituximab | 2 | 2016 | 176 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2021 | 630 | 0.140 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 54 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 238 | 0.130 |
Why?
| | Patient Care Management | 1 | 2017 | 57 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 225 | 0.130 |
Why?
| | Disease Management | 2 | 2018 | 628 | 0.130 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 9 | 0.130 |
Why?
| | Unilateral Breast Neoplasms | 1 | 2016 | 3 | 0.130 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2016 | 16 | 0.130 |
Why?
| | Multivariate Analysis | 3 | 2009 | 1509 | 0.130 |
Why?
| | Margins of Excision | 1 | 2016 | 50 | 0.130 |
Why?
| | Recurrence | 5 | 2018 | 1060 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 6 | 2017 | 389 | 0.120 |
Why?
| | Esthetics | 2 | 2013 | 51 | 0.120 |
Why?
| | Datasets as Topic | 1 | 2016 | 121 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 249 | 0.120 |
Why?
| | Biopsy | 5 | 2022 | 1129 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 220 | 0.110 |
Why?
| | Quality of Life | 2 | 2025 | 2892 | 0.110 |
Why?
| | Risk Factors | 5 | 2022 | 10388 | 0.110 |
Why?
| | Prostate-Specific Antigen | 3 | 2022 | 162 | 0.110 |
Why?
| | Patient Selection | 4 | 2016 | 696 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 285 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2012 | 77 | 0.110 |
Why?
| | Insurance Coverage | 1 | 2016 | 230 | 0.110 |
Why?
| | Propensity Score | 1 | 2016 | 294 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1774 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 240 | 0.110 |
Why?
| | Societies, Medical | 4 | 2016 | 820 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2020 | 2426 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 86 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 327 | 0.110 |
Why?
| | Beauty | 1 | 2013 | 19 | 0.110 |
Why?
| | Receptors, Progesterone | 2 | 2013 | 350 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 3 | 2017 | 1313 | 0.110 |
Why?
| | Lymphatic Irradiation | 2 | 2010 | 10 | 0.100 |
Why?
| | Palliative Care | 2 | 2018 | 758 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2016 | 202 | 0.100 |
Why?
| | Diagnostic Self Evaluation | 1 | 2013 | 23 | 0.100 |
Why?
| | Axilla | 3 | 2007 | 47 | 0.100 |
Why?
| | Confidence Intervals | 1 | 2013 | 329 | 0.100 |
Why?
| | Prospective Studies | 8 | 2022 | 7604 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1396 | 0.100 |
Why?
| | Age Distribution | 1 | 2013 | 392 | 0.100 |
Why?
| | Sex Distribution | 1 | 2013 | 375 | 0.100 |
Why?
| | Lymphatic Metastasis | 4 | 2019 | 352 | 0.100 |
Why?
| | Immunotherapy | 1 | 2016 | 641 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 1994 | 217 | 0.090 |
Why?
| | Cyclophosphamide | 2 | 2009 | 247 | 0.090 |
Why?
| | Health Physics | 1 | 2010 | 5 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2017 | 556 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2006 | 890 | 0.080 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2010 | 30 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1430 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2526 | 0.080 |
Why?
| | Boronic Acids | 1 | 2010 | 37 | 0.080 |
Why?
| | Doxorubicin | 2 | 2009 | 362 | 0.080 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2010 | 106 | 0.080 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 403 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.080 |
Why?
| | Pyrazines | 1 | 2010 | 90 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3958 | 0.070 |
Why?
| | Databases as Topic | 1 | 2008 | 67 | 0.070 |
Why?
| | Iridium Radioisotopes | 1 | 2007 | 4 | 0.070 |
Why?
| | Movement | 1 | 2010 | 278 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2008 | 161 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2010 | 332 | 0.070 |
Why?
| | Positron-Emission Tomography | 3 | 2017 | 294 | 0.070 |
Why?
| | Registries | 1 | 2016 | 2035 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2071 | 0.070 |
Why?
| | Prednisone | 1 | 2008 | 240 | 0.070 |
Why?
| | Comorbidity | 3 | 2017 | 1622 | 0.070 |
Why?
| | Fatigue | 2 | 2025 | 329 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 358 | 0.070 |
Why?
| | Incidence | 1 | 2013 | 2804 | 0.060 |
Why?
| | Sternum | 1 | 2006 | 24 | 0.060 |
Why?
| | Stomatitis | 1 | 2006 | 14 | 0.060 |
Why?
| | Age Factors | 2 | 2017 | 3295 | 0.060 |
Why?
| | Carcinoma, Small Cell | 1 | 2006 | 172 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3457 | 0.060 |
Why?
| | Radiology | 1 | 2008 | 180 | 0.060 |
Why?
| | Conjunctival Neoplasms | 1 | 2025 | 8 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 11 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 117 | 0.060 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2025 | 13 | 0.060 |
Why?
| | Child | 3 | 2024 | 21935 | 0.060 |
Why?
| | Nomograms | 1 | 2025 | 54 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 176 | 0.060 |
Why?
| | Tacrolimus | 1 | 2006 | 199 | 0.060 |
Why?
| | Mastectomy, Modified Radical | 2 | 2000 | 6 | 0.050 |
Why?
| | Anemia, Sideroblastic | 1 | 2003 | 3 | 0.050 |
Why?
| | Living Donors | 1 | 2006 | 295 | 0.050 |
Why?
| | Radiography | 2 | 2010 | 822 | 0.050 |
Why?
| | Reproducibility of Results | 5 | 2012 | 3284 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2009 | 2691 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 801 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2019 | 3566 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2018 | 786 | 0.050 |
Why?
| | Mass Screening | 1 | 2010 | 1287 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 786 | 0.050 |
Why?
| | Lymph Node Excision | 3 | 2009 | 171 | 0.040 |
Why?
| | Professional Staff Committees | 1 | 2001 | 13 | 0.040 |
Why?
| | Allografts | 1 | 2021 | 146 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2021 | 123 | 0.040 |
Why?
| | Organ Size | 2 | 2013 | 477 | 0.040 |
Why?
| | Weight Loss | 1 | 2006 | 787 | 0.040 |
Why?
| | Automation | 1 | 2020 | 95 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2000 | 49 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 227 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 172 | 0.040 |
Why?
| | Quality Assurance, Health Care | 2 | 2012 | 322 | 0.040 |
Why?
| | Risk Management | 1 | 2020 | 93 | 0.040 |
Why?
| | Respiration | 2 | 2010 | 199 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2000 | 142 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 165 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 29 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 327 | 0.040 |
Why?
| | Maximum Tolerated Dose | 2 | 2010 | 199 | 0.030 |
Why?
| | Sulfonamides | 1 | 2021 | 513 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 178 | 0.030 |
Why?
| | Osteoblasts | 1 | 2018 | 126 | 0.030 |
Why?
| | Neutropenia | 2 | 2010 | 146 | 0.030 |
Why?
| | Aftercare | 1 | 2019 | 208 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 795 | 0.030 |
Why?
| | Canada | 1 | 2018 | 418 | 0.030 |
Why?
| | Retreatment | 1 | 2017 | 72 | 0.030 |
Why?
| | Asparaginase | 1 | 2016 | 30 | 0.030 |
Why?
| | Fat Necrosis | 1 | 2016 | 9 | 0.030 |
Why?
| | Metaplasia | 1 | 2016 | 60 | 0.030 |
Why?
| | Safety | 1 | 2018 | 338 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1289 | 0.030 |
Why?
| | Ultrasonography | 1 | 2000 | 759 | 0.030 |
Why?
| | North America | 1 | 2016 | 313 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 493 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2016 | 166 | 0.030 |
Why?
| | Europe | 1 | 2016 | 414 | 0.030 |
Why?
| | Heart | 2 | 2010 | 655 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 991 | 0.030 |
Why?
| | Postmenopause | 2 | 2009 | 366 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1996 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2016 | 150 | 0.030 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 109 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2016 | 139 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 233 | 0.030 |
Why?
| | Advisory Committees | 1 | 2016 | 219 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 318 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 364 | 0.030 |
Why?
| | Radioimmunotherapy | 1 | 2014 | 16 | 0.030 |
Why?
| | Actuarial Analysis | 1 | 1994 | 27 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1070 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 322 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 411 | 0.030 |
Why?
| | Child, Preschool | 1 | 2008 | 11074 | 0.020 |
Why?
| | Treatment Failure | 1 | 1994 | 356 | 0.020 |
Why?
| | Mass Media | 1 | 2012 | 42 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5778 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2001 | 1809 | 0.020 |
Why?
| | Ultrasonography, Mammary | 1 | 2010 | 13 | 0.020 |
Why?
| | Palpation | 1 | 2010 | 15 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.020 |
Why?
| | Urologic Neoplasms | 1 | 2010 | 31 | 0.020 |
Why?
| | Thoracic Neoplasms | 1 | 2010 | 37 | 0.020 |
Why?
| | Bortezomib | 1 | 2010 | 54 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 62 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.020 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 81 | 0.020 |
Why?
| | Nausea | 1 | 2010 | 111 | 0.020 |
Why?
| | Soft Tissue Neoplasms | 1 | 2010 | 115 | 0.020 |
Why?
| | Genital Neoplasms, Female | 1 | 2010 | 90 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 80 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2010 | 179 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2734 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 413 | 0.020 |
Why?
| | Diarrhea | 1 | 2010 | 184 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 140 | 0.020 |
Why?
| | Calcinosis | 1 | 2010 | 235 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 188 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2844 | 0.020 |
Why?
| | Premenopause | 1 | 2009 | 131 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 343 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 63 | 0.020 |
Why?
| | Credentialing | 1 | 2007 | 18 | 0.020 |
Why?
| | Quality Control | 1 | 2008 | 172 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 317 | 0.020 |
Why?
| | Fibrosis | 1 | 2010 | 552 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1704 | 0.020 |
Why?
| | Medicare | 1 | 2012 | 773 | 0.020 |
Why?
| | Lung | 2 | 2010 | 4060 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 740 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1483 | 0.020 |
Why?
| | Benchmarking | 1 | 2007 | 186 | 0.020 |
Why?
| | Taxoids | 1 | 2006 | 102 | 0.020 |
Why?
| | Etoposide | 1 | 2006 | 158 | 0.020 |
Why?
| | Carboplatin | 1 | 2006 | 144 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.020 |
Why?
| | Genital Diseases, Male | 1 | 1985 | 17 | 0.010 |
Why?
| | Colorado | 2 | 2010 | 4565 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2057 | 0.010 |
Why?
| | Genital Diseases, Female | 1 | 1985 | 28 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4149 | 0.010 |
Why?
| | Chlamydia trachomatis | 1 | 1985 | 49 | 0.010 |
Why?
| | Pharynx | 1 | 1985 | 59 | 0.010 |
Why?
| | Siblings | 1 | 2006 | 228 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 434 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1738 | 0.010 |
Why?
| | Cisplatin | 1 | 2006 | 320 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2006 | 156 | 0.010 |
Why?
| | Rectum | 1 | 1985 | 185 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2007 | 956 | 0.010 |
Why?
| | Antilymphocyte Serum | 1 | 2003 | 66 | 0.010 |
Why?
| | Sexually Transmitted Diseases | 1 | 1985 | 161 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2003 | 303 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2003 | 416 | 0.010 |
Why?
| | Graft Rejection | 1 | 2006 | 624 | 0.010 |
Why?
| | Transplantation, Heterologous | 1 | 2001 | 194 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 2009 | 855 | 0.010 |
Why?
| | Organizational Objectives | 1 | 2001 | 73 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 182 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 389 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6079 | 0.010 |
Why?
| | Reoperation | 1 | 2000 | 573 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 6763 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 766 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 1985 | 73 | 0.000 |
Why?
| | Chlamydia Infections | 1 | 1985 | 75 | 0.000 |
Why?
| | Risk | 1 | 1985 | 912 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1985 | 485 | 0.000 |
Why?
|
|
Rabinovitch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|